College of Medicine, Al-Nahrain University, Iraq.
Arch Razi Inst. 2021 Dec 30;76(6):1803-1813. doi: 10.22092/ARI.2021.356195.1800. eCollection 2021 Dec.
The present study aimed to assess the effect of Apremilast on experimentally induced hypertrophic scars in rabbits. A total of 40 healthy male New Zealand White rabbits between 6 and 12 months of age were assigned to four groups (n=10). Group I consists of apparently healthy control rabbits, in group II, the rabbits with an induced hypertrophic scar received no treatment, except for base gel. In group III, the rabbits with induced hypertrophic scar were treated with triamcinolone acetonide (TAC) 0.1% as standard medication. In group IV, rabbits with induced hypertrophic scars were treated with Apremilast 5%. On the first day, four surgical incisions were made using an 8-mm biopsy punch on the ventral surface of the rabbit ear down to cartilage. The TAC and Apremilast were topically administered to the developed scars on day 31. The results included an examination of skin histopathology, the level of transforming growth factor beta-1 (TGF-β1), and collagen III in skin tissue. In the treatments, the inflammatory score, scar index, as well as immunological scores of TGFβ1 and collagen III, significantly decreased, compared to the hypertrophic induced scar group (≤ 0.001). Moreover, there was a significant reduction in fibroblast count, compared to the group of induced hypertrophic scars (<0.05). Apremilast was efficacious in the treatment of hypertrophic scars due to its ability to reduce inflammations and fibroblast counts and scar index. Nonetheless, the reduction of immunological scores was almost comparable to that of topical TAC.
本研究旨在评估阿普米司特对兔实验性增生性瘢痕的影响。将 40 只 6-12 月龄健康雄性新西兰白兔分为 4 组(n=10)。I 组为正常对照兔,II 组为诱导增生性瘢痕兔,除给予基础凝胶外,不给予其他治疗。III 组为诱导增生性瘢痕兔给予曲安奈德(TAC)0.1%作为标准药物治疗。IV 组为诱导增生性瘢痕兔给予阿普米司特 5%治疗。第 1 天,在兔耳腹面用 8mm 活检打孔器切 4 个手术切口,直至软骨。在第 31 天,将 TAC 和阿普米司特局部应用于形成的瘢痕。结果包括皮肤组织病理学检查、转化生长因子β-1(TGF-β1)水平和皮肤组织中胶原 III 的检测。在治疗中,与增生性诱导瘢痕组相比,炎症评分、瘢痕指数以及 TGFβ1 和胶原 III 的免疫评分均显著降低(≤0.001)。此外,与诱导增生性瘢痕组相比,成纤维细胞计数显著减少(<0.05)。阿普米司特通过减少炎症和成纤维细胞计数以及瘢痕指数,对增生性瘢痕的治疗有效。然而,免疫评分的降低几乎与局部 TAC 相当。